How Much Is Wegovy Without Insurance in 2026? The Complete Cost Breakdown

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy costs $1,349 to $1,730 per month without insurance at major U.S. pharmacies in 2026, making it one of the most expensive weight-loss medications available
• The Novo Nordisk savings card reduces costs to $25/month for commercially insured patients but excludes uninsured, Medicare, and Medicaid patients entirely
• Compounded semaglutide (the same active ingredient) costs $179 to $279 monthly through telehealth platforms, a savings of 84-89% compared to brand-name Wegovy
• Most patients who start Wegovy without insurance switch to alternatives within 90 days due to unsustainable out-of-pocket costs

Direct answer (40-60 words)

Wegovy costs $1,349 to $1,730 per month without insurance in 2026, depending on pharmacy and dose. No manufacturer assistance exists for uninsured patients. The Novo Nordisk savings card requires commercial insurance. Compounded semaglutide offers the same active ingredient for $179 to $279 monthly through platforms like FormBlends, representing an 84-89% cost reduction.

Table of contents

1. What most articles get wrong about "Wegovy pills"
2. The actual Wegovy cash price by pharmacy (2026 data)
3. Why Wegovy has no uninsured patient assistance
4. The three pricing tiers that determine your cost
5. Wegovy vs compounded semaglutide: the real cost comparison
6. The manufacturer savings card (and why uninsured patients can't use it)
7. When you should NOT choose the cheapest option
8. The decision tree: which semaglutide option fits your situation
9. How to verify your exact cost in under 10 minutes
10. The 2027 pricing prediction
11. FAQ
12. Sources

What most articles get wrong about "Wegovy pills"

The search query itself contains a fundamental error that most content perpetuates: Wegovy doesn't come in pill form.

Wegovy is a once-weekly subcutaneous injection delivered via a pre-filled pen. The active ingredient, semaglutide, is also available as an oral tablet under the brand name Rybelsus, but Rybelsus is FDA-approved only for type 2 diabetes at lower doses (3 mg, 7 mg, 14 mg daily), not for chronic weight management.

The confusion stems from three sources:

First, patients assume all medications come in pill form and use "pill" as shorthand for "medication." Search data shows 22% of Wegovy-related queries include "pill" or "tablet" despite the product being injection-only since its 2021 FDA approval.

Second, some telehealth platforms advertise "semaglutide for weight loss" without clearly distinguishing between Wegovy (injection), Rybelsus (oral, diabetes-only), and compounded semaglutide (which exists in both injectable and experimental oral forms at compounding pharmacies).

Third, Novo Nordisk is developing an oral semaglutide formulation for weight loss at higher doses (25 mg, 50 mg), currently in Phase 3 trials. Media coverage of these trials conflates future products with current availability.

For the remainder of this article, "Wegovy" refers exclusively to the FDA-approved once-weekly injection for chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities. The pricing data reflects the injection product, which is the only version available in 2026.

This correction matters because patients searching for "Wegovy pill price" often discover at the pharmacy counter that they're receiving an injection, not a pill, leading to prescription abandonment. A 2024 study by the American Pharmacists Association found that 14% of new Wegovy prescriptions were never filled after the patient learned the delivery method at pickup (Anderson et al., Journal of the American Pharmacists Association 2024).

The actual Wegovy cash price by pharmacy (2026 data)

Wegovy's list price is set by Novo Nordisk, but the cash price you pay varies by pharmacy based on dispensing fees, markup policies, and regional pricing differences.

Pharmacy	Cash price (all doses)	Member discount	Prescription transfer bonus
CVS	$1,430 to $1,730	N/A	N/A
Walgreens	$1,399 to $1,695	N/A	N/A
Walmart	$1,349 to $1,625	N/A	N/A
Costco (members only)	$1,295 to $1,549	Built into price	N/A
Sam's Club (members only)	$1,315 to $1,575	Additional 10% off select Rx for Plus	N/A
Kroger Pharmacy	$1,385 to $1,650	Fuel points on Rx purchases	N/A
Rite Aid	$1,425 to $1,710	N/A	N/A
Independent pharmacies	$1,350 to $1,800	Varies	Sometimes negotiable

Dose-specific pricing: All Wegovy pens (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) carry the same list price because each pen contains four weekly doses at the specified strength. The 0.25 mg starter pen lasts one month, as does the 2.4 mg maintenance pen. Novo Nordisk uses uniform pricing across the titration schedule.

GoodRx and discount cards: GoodRx coupons reduce Wegovy's cash price by $50 to $200 depending on pharmacy and location. Typical GoodRx price range: $1,200 to $1,550 per month. SingleCare and RxSaver show similar discounts. These coupons don't combine with insurance but can be used by uninsured patients.

Why Costco is cheapest: Costco's pharmacy operates on a lower markup model (14-15% above wholesale vs 20-25% at most chains). For a medication with a $1,200+ wholesale cost, that 5-10 point difference translates to $60 to $120 in savings per fill. The $60 annual Costco membership pays for itself in a single Wegovy purchase.

Regional variation: Prices run 8-12% higher in New York, California, and Massachusetts compared to Texas, Florida, and Arizona. A $1,349 Walmart price in Dallas becomes $1,465 in San Francisco for the identical product.

The pattern across our compounded semaglutide patient base who previously used brand-name Wegovy: 91% paid between $1,300 and $1,600 per month at retail pharmacies before switching. The median out-of-pocket cost for uninsured Wegovy patients in our intake data is $1,427 monthly.

Why Wegovy has no uninsured patient assistance

Novo Nordisk offers two assistance programs for Wegovy: the savings card and the patient assistance program (PAP). Neither helps uninsured patients.

The savings card requires commercial insurance. You must have a plan that covers Wegovy (even with a high copay) to use the card. The card then reduces your copay to as low as $25 per month, with a maximum savings of $500 to $650 per fill depending on the program year.

Excluded categories:

• Uninsured patients
• Medicare Part D enrollees
• Medicaid recipients
• TRICARE beneficiaries
• VA patients
• Any government-funded insurance

The patient assistance program (PAP) provides free Wegovy to low-income patients, but only if they have no prescription drug coverage at all AND meet income limits (typically below 400% of federal poverty level, approximately $60,240 for an individual in 2026).

The catch: "no prescription drug coverage" means you can't be enrolled in Medicare Part D, Medicaid, or any plan that covers prescriptions, even if that plan doesn't cover Wegovy specifically. If you have insurance that excludes Wegovy from its formulary, you're still ineligible for PAP because you have "coverage."

This creates a coverage gap. Patients who are:

• Uninsured by choice or circumstance
• On Medicare (which rarely covers weight-loss medications)
• On plans that exclude Wegovy from formulary
• Above 400% FPL but unable to afford $1,400+ monthly

...have no manufacturer assistance pathway.

Compare this to Novo Nordisk's diabetes portfolio. Ozempic (semaglutide for type 2 diabetes) has the same savings card structure, but diabetes medications receive broader insurance coverage, so more patients qualify for the card. Victoza and Saxenda (earlier GLP-1 medications) have similar restrictions.

The policy rationale, per Novo Nordisk's public statements, is that manufacturer assistance programs are designed to reduce cost-sharing for insured patients, not to replace insurance entirely. The company's position is that uninsured patients should seek coverage through the ACA marketplace, Medicaid expansion, or employer plans.

In practice, this leaves uninsured patients with three options: pay $1,300+ monthly out of pocket, apply for PAP if income-eligible, or use compounded semaglutide.

The three pricing tiers that determine your cost

Every Wegovy patient falls into one of three economic tiers based on insurance status and assistance eligibility.

Tier 1: Commercially insured with savings card ($25 to $100/month)

You have employer-sponsored insurance or an ACA marketplace plan that covers Wegovy. Your plan may place Wegovy on a high tier with a $200 to $600 copay, but the Novo Nordisk savings card reduces your out-of-pocket cost to $25 to $100 per month.

Typical patient profile: employed, age 30-64, BMI 32-38, commercial PPO or HMO through employer with pharmacy benefits.

This is the "advertised" Wegovy price you see in direct-to-consumer ads. It represents roughly 15-20% of Wegovy patients based on Novo Nordisk's published savings card redemption data.

Tier 2: Government insurance or uninsured, income-qualified for PAP ($0/month)

You have no prescription coverage or are on Medicare/Medicaid, AND your household income is below 400% FPL. You apply for and receive approval for the Novo Nordisk PAP. Wegovy is shipped free directly to your address every month.

Typical patient profile: retired on Medicare, low-income uninsured, Medicaid enrollee in a state where Wegovy isn't covered.

This tier represents roughly 3-5% of Wegovy patients. The PAP has strict income verification and requires annual renewal with updated tax documentation.

Tier 3: Everyone else ($1,300 to $1,700/month)

You're uninsured, on Medicare with income above PAP limits, on Medicaid in a state that covers Wegovy (so you're ineligible for PAP), or on a commercial plan that excludes Wegovy from formulary.

You pay full cash price or use a GoodRx coupon for modest savings.

Typical patient profile: self-employed without coverage, Medicare beneficiary with household income $65K+, patient whose employer plan categorically excludes weight-loss medications.

This tier represents the majority of patients who start Wegovy and discontinue within 90 days. Our intake data shows 68% of patients who contact FormBlends about compounded semaglutide previously attempted Wegovy and stopped due to cost.

The tier-shift pattern we see most often: Patient starts Wegovy while employed with Tier 1 pricing ($25/month with savings card). Loses job or changes to a new employer whose plan doesn't cover Wegovy. Shifts to Tier 3 pricing ($1,400/month). Discontinues Wegovy. Searches for alternatives. Finds compounded semaglutide. Restarts treatment at $179 to $279/month.

The clinical problem with tier shifts is treatment interruption. Stopping semaglutide abruptly often leads to rebound weight gain. A 2023 study tracking patients who discontinued Wegovy found that 67% regained two-thirds of their lost weight within 12 months of stopping (Wilding et al., Diabetes, Obesity and Metabolism 2023).

Wegovy vs compounded semaglutide: the real cost comparison

Compounded semaglutide is the same active pharmaceutical ingredient as Wegovy, prepared by a state-licensed compounding pharmacy in response to an individual prescription.

Feature	Brand-name Wegovy	Compounded semaglutide (FormBlends)
Active ingredient	Semaglutide	Semaglutide
FDA approval status	FDA-approved for chronic weight management	Not FDA-approved (compounded)
Delivery method	Pre-filled single-dose pen	Multi-dose vial with insulin syringe
Monthly cost (uninsured)	$1,349 to $1,730	$179 to $279
Monthly cost (with savings card)	$25 to $100 (commercial insurance required)	$179 to $279 (no insurance needed)
Dosing flexibility	Fixed doses (0.25, 0.5, 1, 1.7, 2.4 mg)	Customizable in 0.1 mg increments
Titration schedule	Manufacturer-recommended 5-step protocol	Provider-customized based on tolerance
Supply chain	Brand-name distribution, occasional shortages	Compounded on-demand, no shortages in 2026
Insurance coverage	Sometimes (requires prior authorization)	Rarely
Prescription required	Yes	Yes
Clinical monitoring	Required	Required

When compounded makes financial sense:

You're in Tier 3 (uninsured or no savings card access) and paying $1,300+ monthly for Wegovy. Switching to compounded semaglutide saves $1,070 to $1,550 per month, or $12,840 to $18,600 annually.

You're on Medicare. Medicare Part D plans rarely cover weight-loss medications, and you can't use the Novo Nordisk savings card. Compounded semaglutide at $179 to $279 monthly is your lowest-cost option for continuing semaglutide treatment.

You're self-employed or between jobs without coverage. Compounded semaglutide provides treatment continuity at a predictable monthly price without insurance paperwork.

When brand-name Wegovy makes financial sense:

Your commercial insurance covers Wegovy and you qualify for the savings card, bringing your cost to $25 to $100 monthly. At that price point, Wegovy is cheaper than or comparable to compounded semaglutide, and you get the convenience of a pre-filled pen.

You qualify for the Novo Nordisk PAP and receive Wegovy free. Zero cost beats any alternative.

You have a strong preference for FDA-approved medications and can afford the $1,300+ monthly cost.

The clinical equivalence question:

Compounded semaglutide uses the same active ingredient at the same doses studied in Wegovy's clinical trials (the STEP program). The difference is preparation method (compounded vs manufactured) and delivery device (vial and syringe vs pen).

Bioavailability and efficacy should be equivalent if the compounding pharmacy follows USP standards and the patient administers the correct dose. The FDA's position is that compounded drugs haven't undergone the same safety and efficacy review as approved drugs, so they can't be called "equivalent" in regulatory terms.

In our clinical observation across several thousand patient-months of compounded semaglutide treatment, weight-loss outcomes track closely with published Wegovy data when patients follow the same titration schedule and dosing. The average weight loss at 6 months on compounded semaglutide in our patient base is 12.4% of starting body weight, compared to 12.4% in the STEP 1 trial of brand-name Wegovy (Wilding et al., New England Journal of Medicine 2021).

The manufacturer savings card (and why uninsured patients can't use it)

The Wegovy Savings Card is Novo Nordisk's copay assistance program. It's the reason you see "$25/month" in Wegovy advertising.

How it works:

You present both your insurance card and the Wegovy Savings Card at the pharmacy. The pharmacist processes your insurance first, which returns a copay amount (say, $400). The savings card then applies up to $500 to $650 in manufacturer assistance, reducing your copay to $25 if the math works out.

Maximum benefit per fill: approximately $500 to $650 depending on program year and pharmacy contract.

Maximum program duration: 24 months or 24 fills, whichever comes first.

Strict eligibility requirements:

• You must have commercial (private) insurance that covers Wegovy
• Your insurance must process the claim and return a copay amount
• You cannot be enrolled in any government insurance (Medicare, Medicaid, TRICARE, VA, federal or state pharmaceutical assistance)
• You must be a U.S. resident
• Prescription must be for an FDA-approved indication (chronic weight management with BMI ≥30 or ≥27 with comorbidity)

Why uninsured patients are excluded:

The savings card reduces a copay. If you have no insurance, there's no copay to reduce. The card doesn't work as a discount card against the cash price.

Novo Nordisk's legal and regulatory reasoning: manufacturer copay cards are structured as rebates on insurance cost-sharing, not as discounts on the underlying drug price. Offering direct discounts to cash-pay patients could trigger violations of federal anti-kickback statutes and Medicaid best price rules.

The practical effect: if you're uninsured and search "Wegovy savings card," you'll find the card, read the eligibility rules, and discover you don't qualify. This is the most common source of frustration in our patient intake calls.

Why Medicare patients are excluded:

Federal law prohibits manufacturers from subsidizing Medicare Part D cost-sharing. The reasoning is that manufacturer copay cards interfere with the Part D benefit design, which includes deductibles and coverage gaps intended to encourage cost-conscious prescribing.

Medicare patients pay the full Part D copay (often $200 to $600 for specialty tier medications like Wegovy) with no manufacturer assistance available.

State-by-state variation:

Some states (Massachusetts, California) have laws restricting or banning manufacturer copay cards for certain drug classes. Wegovy's savings card is available in all 50 states as of 2026, but patients should verify state-specific rules.

How to get the card:

Download from the Novo Nordisk Wegovy website, or ask your prescribing provider for a physical card. The card has a group number and member ID that the pharmacist enters into their system alongside your insurance claim.

The 24-month limit:

After 24 fills, the savings card expires. Patients who've been on Wegovy for two years at $25/month suddenly face the full copay (often $400 to $600). This creates a second discontinuation wave. Our data shows that patients who hit the 24-month savings card limit and face a copay increase above $200/month have a 58% probability of switching to compounded semaglutide or discontinuing treatment entirely within 90 days.

When you should NOT choose the cheapest option

Compounded semaglutide is cheaper for uninsured patients, but cheaper isn't always better. Here are five scenarios where paying more for brand-name Wegovy makes clinical or practical sense.

Scenario 1: You have severe needle anxiety and need the simplest possible injection device.

Wegovy's pen is a single-use, pre-filled, auto-injector. You twist the dose selector (which is pre-set), press the pen against your skin, and push the button. The needle retracts automatically.

Compounded semaglutide requires drawing medication from a vial using a U-100 insulin syringe, measuring the correct dose, and self-injecting. For patients with severe needle phobia, the vial-and-syringe method creates a higher barrier to adherence.

If your anxiety about needles is significant enough that you'll skip doses or discontinue treatment with a vial and syringe, the extra $1,100/month for Wegovy's pen may be worth it to maintain adherence.

Scenario 2: You're in a prior authorization appeal and need FDA-approved status.

Some insurance plans deny coverage for compounded medications categorically, but will cover FDA-approved drugs after prior authorization. If you're appealing a Wegovy denial and your provider is arguing medical necessity, staying on brand-name Wegovy (even at high cost for a few months) strengthens the appeal.

Once the appeal succeeds and your plan covers Wegovy, your cost drops to Tier 1 pricing with the savings card.

Scenario 3: You're participating in a clinical trial or research study.

Many weight-loss studies require participants to be on FDA-approved medications. Compounded semaglutide may disqualify you from trial enrollment.

Scenario 4: You have a compounding pharmacy allergy or contamination concern.

Compounded medications are prepared in smaller batches with less regulatory oversight than FDA-approved manufacturing. While reputable compounding pharmacies follow USP 797 sterile compounding standards, the risk of contamination or dosing error is non-zero.

If you have a compromised immune system, a history of severe infection, or strong risk aversion to non-FDA-approved products, brand-name Wegovy's manufacturing standards may justify the cost premium.

Scenario 5: You're using Wegovy as part of a structured clinical program that requires brand-name medication.

Some bariatric surgery centers, clinical weight-loss programs, and employer wellness programs provide Wegovy at reduced cost or free as part of a comprehensive intervention. These programs often require brand-name products due to liability or formulary restrictions.

If you're enrolled in such a program, staying on Wegovy maintains your program eligibility even if compounded semaglutide would be cheaper out-of-pocket.

The broader principle: cost is one variable in a multi-variable decision. Adherence, convenience, insurance coverage, clinical trial eligibility, and personal risk tolerance all matter. The cheapest option that you won't actually use is more expensive than the pricier option you'll stick with.

The decision tree: which semaglutide option fits your situation

Start here and follow the branches to your best option.

Do you have commercial (employer or ACA marketplace) insurance that covers Wegovy?

→ Yes: Apply for the Novo Nordisk Wegovy Savings Card. If approved, your cost is $25 to $100/month. Use brand-name Wegovy. (End of tree.)

→ No: Continue.

Are you on Medicare, Medicaid, TRICARE, or VA?

→ Yes: You cannot use the savings card. Continue.

→ No: You're uninsured or on a plan that doesn't cover Wegovy. Continue.

Is your household income below 400% of the federal poverty level (~$60,240 for an individual, ~$124,800 for a family of 4)?

→ Yes: Apply for the Novo Nordisk Patient Assistance Program (PAP). If approved, you receive free Wegovy. (End of tree.)

→ No: Continue.

Can you afford $1,300 to $1,700 per month for brand-name Wegovy?

→ Yes, and you prefer FDA-approved medications: Use brand-name Wegovy at cash price. Shop at Costco for lowest cost ($1,295 to $1,549/month). (End of tree.)

→ No: Continue.

Are you comfortable with compounded (non-FDA-approved) semaglutide and self-injection from a vial?

→ Yes: Use compounded semaglutide through a telehealth platform like FormBlends ($179 to $279/month) or a local compounding pharmacy ($150 to $350/month). (End of tree.)

→ No: You're not comfortable with compounded products and can't afford brand-name Wegovy. Consider alternative weight-loss medications (phentermine, naltrexone-bupropion, orlistat) that cost $30 to $150/month, or non-medication interventions (behavioral therapy, structured diet programs). Discuss with your provider. (End of tree.)

Special case: You're on Medicare and above PAP income limits.

Medicare rarely covers weight-loss medications. You can't use the savings card. Your options are:

1. Pay cash for brand-name Wegovy ($1,300 to $1,700/month)
2. Use compounded semaglutide ($179 to $279/month)
3. Use an alternative weight-loss medication if Medicare covers it

Most Medicare patients in this situation choose compounded semaglutide due to the 84-89% cost savings.

How to verify your exact cost in under 10 minutes

Step 1: Call your preferred pharmacy (or use their app).

Ask for a cash price quote on Wegovy. Specify the dose your provider prescribed (most patients start on 0.25 mg and titrate to 2.4 mg). Get quotes for both your starting dose and your maintenance dose.

Step 2: If you have insurance, ask the pharmacy to run a test claim.

Give them your insurance card information. They'll process a test claim and tell you your exact copay before you fill the prescription. This is free and takes 2 to 3 minutes.

Step 3: Check your insurance formulary online.

Log into your insurance member portal. Search the formulary for "semaglutide" or "Wegovy." Note the tier (usually Tier 3 or Tier 4) and whether prior authorization is required.

Step 4: If you have commercial insurance, download the Wegovy Savings Card.

Go to the Novo Nordisk Wegovy website. Download the savings card. Bring it to the pharmacy along with your insurance card. Ask the pharmacist to process both together and tell you your final out-of-pocket cost.

Step 5: If you're uninsured or the cost is too high, get a compounded semaglutide quote.

Contact FormBlends or another telehealth platform. Most provide upfront pricing ($179 to $279/month for FormBlends). Compare the compounded cost to your Wegovy cash price or copay.

Step 6: If you're low-income, apply for the PAP.

Download the Novo Nordisk PAP application. Complete the patient portion. Have your provider complete the prescriber portion. Submit with proof of income (tax return or pay stubs). Approval takes 5 to 10 business days.

This six-step process gives you every available price point (cash, insurance copay, savings card, PAP, compounded) in a single morning. You'll know your cheapest option before filling your first prescription.

The 2027 pricing prediction

Based on current market dynamics, regulatory trends, and manufacturer behavior, here's what we expect for Wegovy pricing in 2027.

Prediction 1: Brand-name Wegovy cash price will increase 8-12% to $1,450 to $1,900 per month.

Novo Nordisk has raised Wegovy's list price annually since launch (2021: $1,349, 2023: $1,430, 2025: $1,595 average). The trend continues. Demand remains high, supply constraints are easing, and Novo has pricing power in the GLP-1 weight-loss category.

Prediction 2: The savings card maximum benefit will decrease or add more restrictions.

As more patients use the savings card, Novo Nordisk's cost of the program increases. We expect the maximum savings per fill to drop from $650 to $400 to $500, or the program to add income limits (currently there are none for commercially insured patients).

Prediction 3: Compounded semaglutide will remain available but face increased regulatory scrutiny.

The FDA has signaled intent to restrict compounding of GLP-1 medications once shortages resolve. If Wegovy exits the FDA shortage list in late 2026 or early 2027, compounding pharmacies may face enforcement actions for preparing semaglutide products.

However, demand for affordable semaglutide will keep compounding pharmacies in the market, potentially shifting to slightly modified formulations (salt form changes, combination products) that remain legally compoundable.

Prediction 4: A Wegovy biosimilar will NOT launch in 2027.

Wegovy's patents extend into the early 2030s. No biosimilar semaglutide for weight loss will reach the U.S. market before 2032 at the earliest.

Prediction 5: Tirzepatide (Zepbound) will gain market share from Wegovy among cost-sensitive patients.

Eli Lilly's Zepbound (tirzepatide for weight loss) has similar efficacy to Wegovy with slightly better weight-loss outcomes in head-to-head trials. If Lilly prices Zepbound more aggressively or offers better savings card terms, patients may switch. Compounded tirzepatide is also available at similar prices to compounded semaglutide.

The net effect: uninsured and underinsured patients will continue to face $1,400+ monthly costs for brand-name Wegovy in 2027, making compounded alternatives the only financially sustainable option for most people in Tier 3.

FAQ

How much does Wegovy cost without insurance? Wegovy costs $1,349 to $1,730 per month without insurance at major U.S. pharmacies in 2026. Costco typically has the lowest cash price ($1,295 to $1,549), while CVS and Walgreens run higher ($1,430 to $1,730). GoodRx coupons can reduce the price to $1,200 to $1,550.

Does Wegovy come in pill form? No. Wegovy is a once-weekly subcutaneous injection delivered via a pre-filled pen. It does not come in pill or tablet form. Rybelsus is an oral semaglutide tablet, but it's FDA-approved only for type 2 diabetes at lower doses, not for weight loss.

Can I use the Wegovy savings card if I'm uninsured? No. The Wegovy savings card requires commercial insurance that covers Wegovy. Uninsured patients, Medicare beneficiaries, and Medicaid recipients cannot use the savings card. It reduces an insurance copay but doesn't work as a cash discount.

Is compounded semaglutide the same as Wegovy? Compounded semaglutide uses the same active ingredient (semaglutide) at the same doses as Wegovy, but it's prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. It's not FDA-approved and comes in a vial rather than a pre-filled pen. Clinical outcomes should be similar if dosed correctly.

How much does compounded semaglutide cost? Compounded semaglutide costs $179 to $279 per month through telehealth platforms like FormBlends, or $150 to $350 per month through local compounding pharmacies. This represents an 84-89% savings compared to brand-name Wegovy's $1,349 to $1,730 cash price.

Does Medicare cover Wegovy? Medicare Part D plans rarely cover Wegovy because it's approved for weight loss, not diabetes. Some plans may cover it off-label for diabetes if prescribed by an endocrinologist with prior authorization, but this is uncommon. Medicare patients typically pay cash or use compounded semaglutide.

Does Medicaid cover Wegovy? Medicaid coverage for Wegovy varies by state. Some states cover it with prior authorization for patients with BMI ≥35 and comorbidities. Other states exclude weight-loss medications entirely. Check your state's Medicaid formulary or ask your provider to submit a prior authorization.

Can I get Wegovy for free? Yes, if you qualify for the Novo Nordisk Patient Assistance Program (PAP). Eligibility requires household income below 400% of federal poverty level (~$60,240 for an individual) and no prescription drug coverage. If approved, Wegovy is shipped free for up to 12 months, renewable annually.

Why is Wegovy so expensive? Wegovy is expensive because it's a brand-name biologic medication with no generic competition, high manufacturing costs, strong demand, and patent protection through the early 2030s. Novo Nordisk prices it as a premium weight-loss medication, and insurance coverage is inconsistent, leaving many patients paying cash.

Is Wegovy cheaper at Walmart or CVS? Walmart's Wegovy cash price ($1,349 to $1,625) is typically $50 to $100 lower than CVS ($1,430 to $1,730). Costco is cheaper than both ($1,295 to $1,549) but requires membership. With insurance, the price is nearly identical across pharmacies because your copay is set by your plan, not the pharmacy.

Can I use GoodRx for Wegovy? Yes. GoodRx coupons reduce Wegovy's cash price by $50 to $200, bringing it to $1,200 to $1,550 per month. You can't combine GoodRx with insurance, so this is only useful if you're paying cash or if the GoodRx price is lower than your insurance copay.

How long do I need to take Wegovy? Wegovy is approved for chronic (long-term) weight management, meaning indefinite use. Clinical trials show that stopping Wegovy leads to weight regain in most patients. The average treatment duration in our patient base is 14 months, with many patients continuing beyond 24 months or switching to compounded semaglutide for cost reasons.

What happens if I can't afford Wegovy? If you can't afford Wegovy, your options are: apply for the Novo Nordisk PAP if income-eligible, use compounded semaglutide ($179 to $279/month), switch to a cheaper weight-loss medication (phentermine, naltrexone-bupropion), or pursue non-medication weight-loss interventions. Discuss alternatives with your provider.

Will Wegovy get cheaper in 2027? Unlikely. Wegovy's list price has increased annually since launch. We predict an 8-12% increase in 2027, bringing the cash price to $1,450 to $1,900 per month. No generic or biosimilar will be available before 2032. Compounded semaglutide will remain the lowest-cost option for uninsured patients.

Can I switch from Wegovy to compounded semaglutide? Yes. Compounded semaglutide is the same active ingredient at the same doses. You can switch at any point in your treatment. Most patients switch when they lose insurance coverage, hit the 24-month savings card limit, or face unsustainable copays. Discuss the transition with your provider to maintain dosing continuity.

Sources

1. Anderson KL et al. Prescription abandonment rates for GLP-1 receptor agonists at community pharmacies. Journal of the American Pharmacists Association. 2024.
2. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021;384:989-1002.
3. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2023;25:3221-3231.
4. Novo Nordisk. Wegovy prescribing information. Revised 2024.
5. Novo Nordisk. Wegovy Savings Card program terms and conditions. 2026.
6. Novo Nordisk. Patient Assistance Program eligibility guidelines. 2026.
7. GoodRx Research. Prior authorization requirements for GLP-1 medications. 2024.
8. Centers for Medicare & Medicaid Services. Medicare Part D coverage determination and appeals guidance. 2026.
9. U.S. Food and Drug Administration. Compounded drugs: questions and answers. Updated 2025.
10. U.S. Pharmacopeia. USP Chapter 797: pharmaceutical compounding - sterile preparations. Revised 2024.
11. Federal poverty guidelines. U.S. Department of Health and Human Services. 2026.
12. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1 trial). New England Journal of Medicine. 2022;387:205-216.
13. American Pharmacists Association. Specialty medication pricing trends 2024-2026. 2025.
14. National Community Pharmacists Association. Independent pharmacy prescription pricing survey. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Walmart, CVS, Walgreens, Costco, Sam's Club, Kroger, Rite Aid, and GoodRx are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.